Fig. 1 · Structure

Documents & Downloads

Gingerol

Cat. No. A12010 CAS 23513-14-6
Gingerol, a phenolic substance and a potent cardiotonic agent isolated from the rhizome of ginger, has been shown to stimulate the Ca2+-pumping activity of sarcoplasmic reticulum (SR) of rabbits in a concentration-dependent manner.

In Stock

Publications for Gingerol

1 publication citing this product

  1. Ramadan A Ali, .et al. , JCI Insight, 2021, Feb 8;6(3):138385 PMID: 33373329

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In primary human neutrophil lysates, 6-gingerol at 10 μM reduced cAMP-specific phosphodiesterase activity by a reported 40%. This assay supports PDE inhibition as a candidate mechanism, but does not establish PDE4 isoform selectivity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
AMPK  
Apoptosis  

Cellular Effect

Cell Line Activity Value Description Reference
DU-145 IC50 95 mg/mL Antiproliferative activity against human DU145 cells after 72 hrs by Alamar blue assay [PMID: 31336310]
LNCaP IC50 75 mg/mL Antiproliferative activity against human LNCAP cells after 72 hrs by Alamar blue assay [PMID: 31336310]
LNCaP C4-2 IC50 512 mg/mL Antiproliferative activity against human C4-2 cells after 72 hrs by Alamar blue assay [PMID: 31336310]
LNCaP C4-2B IC50 240 mg/mL Antiproliferative activity against human C4-2B cells after 72 hrs by Alamar blue assay [PMID: 31336310]
NCI-H1299 IC50 150 μM Cytotoxicity against human H1299 cells assessed as growth inhibition after 24 hrs by MTT assay [PMID: 22246389]
PC-3 IC50 250 mg/mL Antiproliferative activity against human PC3 cells after 72 hrs by Alamar blue assay [PMID: 31336310]
RBL-2H3 IC50 185.1 μM Cytotoxicity against rat RBL2H3 cells after 12 hrs by MTT assay [PMID: 19271742]

In Vitro Studies

In healthy-donor human neutrophils, 10 μM 6-gingerol reduced NET release elicited by RNP immune complexes or APS IgG over 3 hours, as assessed by NET-associated MPO activity and microscopy. A separate 3-hour viability control showed no significant reduction with 1 mM 6-gingerol; this finding has a short-term assay scope. [1]

Inhibition of cAMP-specific PDE activity in neutrophil lysate

Biochemical assay · Lysates from primary human neutrophils [1]

At 10 μM, 6-gingerol reduced cAMP-specific PDE activity relative to the untreated lysate reaction. Rolipram was a comparator; this assay does not establish PDE4 selectivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cAMP-specific PDE activity relative to mean controlreported reduction 40% with 6-gingerol; 50% with rolipram[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM 6-gingerol; comparator rolipram 0.1 μM
Exposure duration
1 hour reaction at 37°C
Method
6-Gingerol or rolipram added to the reaction containing human neutrophil lysate supernatant; cAMP-specific PDE activity measured with a Bridge-It cAMP-PDE assay kit.
Reported limits
Treatment solvent and exact PDE isoform composition not reported in the relevant assay methods; no purified PDE4 selectivity or IC50 experiment.
Methods and source locations

Compound reported in the paper: 6-Gingerol; Compound label in the paper: 6-Gingerol

Evidence applies to 6-gingerol as reported in the paper; no validation of the stereochemical purity or performance of a current Adooq lot.

Figure 3A; Methods: Measurement of PDE activity

cAMP-specific PDE activity relative to mean control: Bridge-It cAMP-PDE fluorescence assay; activity normalized to mean control values. Figure 3 caption reports mean and SEM, n = 3–4 independent experiments across panels. — Results: 6-Gingerol inhibits cAMP-specific PDE activity; Figure 3A and caption; Methods: Measurement of PDE activity

Suppression of autoantibody-associated NET release

Cell-based study · Primary human neutrophils from healthy volunteers stimulated separately with RNP immune complexes or APS IgG [1]

6-Gingerol reduced stimulated NET-associated MPO activity. Neutrophil-elastase/DNA microscopy supported reduced extracellular NET structures. A separate short-term viability control showed no significant change with 1 mM 6-gingerol.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
NET-associated myeloperoxidase after RNP immune-complex or APS-IgG stimulationdirectional comparison Reduced versus the corresponding stimulated group without 6-gingerol[1]
Extracellular NET structuresqualitative microscopy Reduced extracellular neutrophil-elastase/DNA structures with 6-gingerol[1]
Short-term neutrophil viability in a separate controlsignificance No significant reduction at 1 mM 6-gingerol for 3 hours[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM 6-gingerol; RNP immune complexes or APS IgG at 10 μg/mL
Exposure duration
3 hours
Method
Primary human neutrophils from healthy volunteers exposed to the indicated sterile autoimmune stimulus with or without 6-gingerol; NET-associated MPO activity and immunofluorescence assessed.
Co-treatment
RNP immune complexes or APS IgG are activating stimuli, tested separately.
Reported limits
The 6-gingerol treatment solvent, catalog number and enantiomeric composition are not specified in the relevant methods. The separate viability control used 1 mM for 3 hours.
Methods and source locations

Compound reported in the paper: 6-Gingerol; Compound label in the paper: 6-Gingerol

Evidence applies to 6-gingerol as reported in the paper; no validation of the stereochemical purity or performance of a current Adooq lot.

Figure 1E–G; Supplemental Figure 1C; Methods: Human neutrophil purification and NETosis assays; Immunofluorescence microscopy

NET-associated myeloperoxidase after RNP immune-complex or APS-IgG stimulation: Enzymatic activity of nuclease-liberated NET-associated MPO; unstimulated and stimulus-only controls. Figure 1E–F: mean and SEM, n = 3 independent experiments; Dunnett-corrected one-way ANOVA. No exact effect size inferred from bars. — Figure 1E–F and caption; Results: Gingerols inhibit NETosis elicited by lupus and APS autoantibodies; Methods: Human neutrophil purification and NETosis assays

Extracellular NET structures: Immunofluorescence microscopy; vehicle comparator; Hoechst-stained DNA and extracellular neutrophil elastase. Representative images do not provide an independent quantitative effect estimate. — Figure 1G and caption; Methods: Immunofluorescence microscopy

Short-term neutrophil viability in a separate control: Trypan-blue exclusion/counting; untreated control and staurosporine positive control. Mean and SEM, n = 3 independent experiments; NS as labeled. This does not establish longer-term or clinical safety. — Supplemental Figure 1C and caption (SI PDF page 2)

In Vivo Studies

In male C57BL/6 mice with APS-IgG-accelerated venous thrombosis, daily intraperitoneal 6-gingerol at 10 mg/kg, begun 1 day before surgery, reduced serum MPO-DNA complexes and thrombus length and weight at 24 hours. The experiment does not separate antineutrophil from possible antiplatelet contributions. [1]

Attenuation of APS-IgG-accelerated venous thrombosis

Animal study · Male C57BL/6 mice in an electrolytic inferior vena cava thrombosis model [1]

6-Gingerol reduced serum MPO-DNA complexes and thrombus length and weight in APS-IgG-treated mice. Results concern a prophylactic injected-compound model; the contribution of platelet effects versus NET suppression was not separated.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Serum MPO-DNA complexesdirectional comparison Lower with 6-gingerol in APS-IgG-treated mice[1]
Thrombus length and weight 24 hours after surgerydirectional comparison Both lower with 6-gingerol in APS-IgG-treated mice[1]

Conditions shared by the study groups

Route
Intraperitoneal injection
Frequency
Daily
Treatment course
Started 1 day before surgery and continued through the experiment; thrombosis assessed at 24 hours.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
APS IgG plus 6-gingerol
10 mg/kg
APS IgG without 6-gingerol; control IgG with or without 6-gingerol also shown.Reduced serum MPO-DNA complexes, thrombus length and thrombus weight compared with APS IgG without 6-gingerol.[1]
APS IgG plus 6-gingerol
Model: Male C57BL/6 mice in the venous thrombosis model
Reported limits: Injection vehicle, age and explicit group n not stated in the relevant methods/caption.
Methods and source locations

Compound reported in the paper: 6-Gingerol; Compound label in the paper: 6-Gingerol

Evidence applies to 6-gingerol as reported in the paper; no validation of the stereochemical purity or performance of a current Adooq lot.

Figure 6B–E; Methods: Animal housing and treatments; In vivo venous thrombosis

Serum MPO-DNA complexes: MPO-DNA immunoassay; APS-IgG group without 6-gingerol and control-IgG groups as comparators. No exact OD values estimated from the figure. — Figure 6B and caption; Results: 6-Gingerol attenuates aPL-mediated venous thrombosis; Methods: Quantification of MPO-DNA complexes

Thrombus length and weight 24 hours after surgery: Length and weight measured after euthanasia; Figure 6C–D and representative thrombi in 6E. One-way ANOVA with Dunnett correction reported; no exact millimeter or milligram values inferred. — Figure 6C–E and caption; Methods: In vivo venous thrombosis

APS IgG plus 6-gingerol · Figure 6B–E; Methods: Animal housing and treatments; In vivo venous thrombosis

Specifications

Manufacturer Adooq Bioscience
CAS Number 23513-14-6
Formula C17H26O4
Molecular Weight 294.39
Synonyms 6-Gingerol
SMILES
CCCCC[C@@H](CC(=O)CCC1=CC(=C(C=C1)O)OC)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 56 mg/mL (190.22 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Ramadan A. Ali, Alex A. Gandhi, Lipeng Dai, et al. Antineutrophil properties of natural gingerols in models of lupus JCI Insight (2021). PMID: 33373329 DOI: 10.1172/jci.insight.138385 Source material

Publications

1 publication citing this product

  1. Ramadan A Ali, .et al. , JCI Insight, 2021, Feb 8;6(3):138385 PMID: 33373329

Added to your cart

View Cart Checkout
Loading...